The number of gay and bisexual men (GBM) taking HIV pre-exposure prophylaxis (PrEP) to prevent HIV has rapidly increased since 2010, but limited information about barriers and facilitators to adherence has been reported outside of formal trial settings. We conducted semistructured in-depth interviews with 24 Australian cis- and transgender GBM with a history of PrEP use to gather data on adherence to PrEP. The majority of participants were able to access PrEP at no cost through implementation studies. Three key domains were explored—how individuals took PrEP, factors that aided PrEP adherence, and barriers to PrEP use. All participants recognized the importance of regular dosing to ensure protection from HIV, with some participants taking the initiative to pre-empt possible adherence obstacles and plan around these. Multiple strategies were used to aid adherence, including using tools such as a phone alarm and support and tips from other PrEP users, friends, or clinicians. Barriers to PrEP adherence included stigma, concerns about side effects, and difficulties in accessing PrEP. Although most participants encountered at least one barrier to PrEP use, they were resourceful and utilized a variety of approaches to ensure good adherence to PrEP was maintained. These narratives highlight a commitment to finding ways to make PrEP work in the daily lives of this cohort of Australian GBM, demonstrated by their active investigation of different routines to determine the most suitable dosing strategy, and creation of contingency plans if they were unable to access PrEP in their usual or preferred manner.
Get full access to this article
View all access options for this article.
References
1.
McCormackS, DunnDT, DesaiM, et al.Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a Pragmatic Open-Label Randomised Trial. Lancet, 2016; 387:53–60.
2.
AndersonPL, GliddenDV, LiuA, et al.Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med, 2012; 4:151ra25.
3.
MolinaJM, CharreauI, SpireB, et al.Efficacy of on Demand PrEP with TDF-FTC in the ANRS IPERGAY Open-Label Extension Study. AIDS: Durban, South Africa; 2016 [Abstract 2564].
4.
MolinaJM, CapitantC, SpireB, et al.On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. New Engl J Med, 2015; 373:2237–2246.
5.
WrightE, GrulichA, RoyK, et al.Australasian Society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: Clinical Guidelines. J Virus Erad, 2017; 3:168–184.
6.
BekkerLG, RebeK, VenterF, et al.Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. South Afr J HIV Med, 2016; 17:455.
7.
US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States 2014—A Clinical Practice Guideline. Atlanta, GA: Centers for Disease Control and Prevention, 2014.
8.
EACS. European AIDS Clinical Society Guidelines Version 8.0. London: European AIDS Clinical Society, 2015.
9.
WHO. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations—2016 Update. France: World Health Organisation, 2016.
10.
GrantRM, LamaJR, AndersonPL, et al.Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med, 2010; 363:2587–2599.
11.
AmicoKR, MarcusJL, McMahanV, et al.Study product adherence measurement in the iPrEx placebo-controlled trial: Concordance with drug detection. J Acquir Immune Defic Syndr, 2014; 66:530–537.
12.
GafosM, WhiteD, ClarkeA, et al.Adherence Intentions, Long-Term Adherence and HIV Acquisition Among PrEP Users in the PROUD Open-Label Randomised Control Trial of PrEP in England. Paris, France: IAS; 2017 [Abstract 3944].
13.
MolinaJM, CharreauI, SpireB, et al.Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: An Observational Cohort Study. Lancet HIV, 2017; 4:e402–e410.
14.
GrantRM, AndersonPL, McMahanV, et al.Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A Cohort Study. Lancet Infect Dis, 2014; 14:820–829.
15.
GengiahTN, MoosaA, NaidooA, et al.Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm, 2014; 36:70–85.
16.
Van der ElstEM, MboguaJ, OperarioD, et al.High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: Qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav, 2013; 17:2162–2172.
17.
CarrilloJE, CarrilloVA, PerezHR, et al.Defining and targeting health care access barriers. J Health Care Poor Underserved, 2011; 22:562–575.
18.
LiuA, GliddenDV, AndersonPL, et al.Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr, 2014; 67:528–537.
19.
Doblecki-LewisS, LiuA, FeasterD, et al.Healthcare access and PrEP continuation in San Francisco and Miami after the US PrEP Demo Project. J Acquir Immune Defic Syndr, 2017; 74:531–538.
20.
AmicoKR, MehrotraM, Avelino-SilvaVI, et al.Self-reported recent PrEP dosing and drug detection in an Open Label PrEP Study. AIDS Behav, 2016; 20:1535–1540.
21.
HoaglandB, MoreiraRI, De BoniRB, et al.High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV infection: The PrEP Brasil Demonstration Project. J Int AIDS Soc, 2017; 20:21472.
22.
MayerKH, OldenburgCE, NovakDS, et al.Early adopters: Correlates of HIV chemoprophylaxis use in recent online samples of US men who have sex with men. AIDS Behav, 2016; 20:1489–1498.
23.
GandhiM, MurnanePM, BacchettiP, et al.Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. AIDS, 2017; 31:2245–2251.
24.
PengP, SuS, FairleyCK, et al.A global estimate of the acceptability of pre-exposure prophylaxis for HIV among men who have sex with men: A systematic review and meta-analysis. AIDS Behav, 2018; 22:1063–1074.
25.
ArnoldT, Brinkley-RubinsteinL, ChanPA, et al.Social, structural, behavioral and clinical factors influencing retention in pre-exposure prophylaxis (PrEP) care in Mississippi. PLoS One, 2017; 12:e0172354.
26.
BuchbinderSP, LiuAY, CROI. 2015: Advances in HIV testing and prevention strategies. Top Antivir Med, 2015; 23:8–27.
27.
MartinM, VanichseniS, SuntharasamaiP, et al.The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS, 2015; 29:819–824.
28.
OldenburgCE, MittyJA, BielloKB, et al.Differences in attitudes about HIV pre-exposure prophylaxis use among stimulant versus alcohol using men who have sex with men. AIDS Behav, 2016; 20:1451–1460.
29.
GliddenDV, AmicoKR, LiuAY, et al.Symptoms, side effects and adherence in the iPrEx Open-Label Extension. Clin Infect Dis, 2016; 62:F1172–F1177.
30.
MulliganK, GliddenDV, AndersonPL, et al.Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis, 2015; 61:572–580.
31.
HosekSG, SiberryG, BellM, et al.The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr, 2013; 62:447–456.
32.
ManingatP, GordonBR, BreslowJL. How do we improve patient compliance and adherence to long-term statin therapy?. Curr Atheroscler Rep, 2013; 15:291.
33.
BrownMT, BussellJK. Medication adherence: Who cares?. Mayo Clin Proc, 2011; 86:304–314.
34.
VaccherSJ, GianacasC, TempletonDJ, et al.Baseline preferences for daily, event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the PRELUDE Demonstration Project. Front Public Health, 2017; 5:341.
35.
ElsesserSA, OldenburgCE, BielloKB, et al.Seasons of risk: Anticipated behavior on vacation and interest in episodic antiretroviral pre-exposure prophylaxis (PrEP) among a large national sample of U.S. men who have sex with men (MSM). AIDS Behav, 2016; 20:1400–1407.
36.
BourneA, CassolatoM, Thuan WeiCK, et al.Willingness to use pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Malaysia: Findings from a Qualitative Study. J Int AIDS Soc, 2017; 20:21899.
37.
GrovC, WhitfieldTH, RendinaHJ, et al.Willingness to take PrEP and potential for risk compensation among highly sexually active gay and bisexual men. AIDS Behav, 2015; 19:2234–2244.
38.
HoltM, MurphyDA, CallanderD, et al.Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect, 2012; 88:258–263.
39.
GaleaJT, KinslerJJ, SalazarX, et al.Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: Barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS, 2011; 22:256–262.
40.
LorenteN, FugonL, CarrieriMP, et al.Acceptability of an “on-Demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care, 2012; 24:468–477.
41.
Perez-FigueroaRE, KapadiaF, BartonSC, et al.Acceptability of PrEP uptake among racially/ethnically diverse young men who have sex with men: The P18 Study. AIDS Educ Prev, 2015; 27:112–125.
42.
ParsonsJT, RendinaHJ, LassiterJM, et al.Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States. J Acquir Immune Defic Syndr, 2017; 74:285–292.
43.
KrakowerDS, WareNC, MaloneyKM, et al.Differing experiences with pre-exposure prophylaxis in Boston among lesbian, gay, bisexual, and transgender specialists and generalists in primary care: Implications for scale-up. AIDS Patient Care STDs, 2017; 31:297–304.
44.
MarksSJ, MerchantRC, ClarkMA, et al.Potential healthcare insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. AIDS Patient Care STDs, 2017; 31:470–478.
45.
Mera GilerR, TrevorH, BushS, et al.Changes in Truvada (TVD) for HIV Pre-Exposure Prophylaxis (PrEP) Utilization in the United States: (2012–2016). Paris, France: IAS; 2017 [Abtract 10159].
46.
MolinaJM, OhayonM, CotteL, et al.One-Year Experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC. Paris, France: IAS; 2017 [Abstract WEPEC0939].
47.
GrulichA. Taking PrEP to Scale for Gay and Bisexual Men in Australia. Paris, France: IAS; 2017 [Abstract SUSA0705].
48.
CorneliAL, DeeseJ, WangM, et al.Fem-PrEP: Adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr, 2014; 66:324–331.
49.
GilmoreHJ, LiuA, KoesterKA, et al.Participant experiences and facilitators and barriers to pill use among men who have sex with men in the IPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDS, 2013; 27:560–566.
50.
VaccherS, GrulichA, McAllisterJ, et al.Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: The NSW Demonstration Project PrELUDE. BMJ Open, 2016; 6:e012179.
51.
NealeJ. Iterative categorization (Ic): A systematic technique for analysing qualitative data. Addiction, 2016; 111:1096–1106.
52.
BraunV, ClarkeV. Using thematic analysis in psychology. Qual Res Psychol, 2006; 3:77–101.
53.
SolomonA, SchoenthalerA, SeixasA, et al.Medication routines and adherence among hypertensive African Americans. J Clin Hypertens (Greenwich), 2015; 17:668–672.
54.
StawarzK, BlandfordA. Don't Forget Your Pill! Designing effective medication reminder apps that support users' daily routines. Proceedings of the SIGCHI Conference on Human Factors in Computing Systems, Toronto, Canada2014; 2269–2278.
55.
RimandoM. Perceived barriers to and facilitators of hypertension management among underserved African American older adults. Ethn Dis, 2015; 25:329–336.
56.
ChlebowyDO, HoodS, LaJoieAS. Facilitators and barriers to self-management of type 2 diabetes among urban African American adults: Focus group findings. Diabetes Educ, 2010; 36:897–905.
57.
RottmanBM, MarcumZA, ThorpeCT, et al.Medication adherence as a learning process: Insights from cognitive psychology. Health Psychol Rev, 2017; 11:17–32.
58.
HaireB. Preexposure prophylaxis-related stigma: Strategies to improve uptake and adherence—A narrative review. HIV AIDS (Auckl), 2015; 7:241–249.
59.
GraceD, JollimoreJ, MacPhersonP, et al.The pre-exposure prophylaxis (PrEP)-stigma paradox: Learning from Canada's first wave of PrEP users. AIDS Patient Care STDS, 2018; 32:24–30.
60.
VaccherS, KannangaraDR, BaysariMT, et al.Barriers to care in gout: From prescriber to patient. J Rheumatol, 2016; 43:144–149.
61.
XuW, LuW, ZhouY, et al.Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: A Qualitative and Quantitative Study. BMC Health Serv Res, 2009; 9:169.
62.
GrivaK, NgHJ, LoeiJ, et al.Managing treatment for end-stage renal disease—A qualitative study exploring cultural perspectives on facilitators and barriers to treatment adherence. Psychol Health, 2013; 28:13–29.
63.
LaceyJ, CateH, BroadwayDC. Barriers to adherence with Glaucoma medications: A Qualitative Research Study. Eye (Lond), 2009; 23:924–932.
64.
LehaneE, McCarthyG. Intentional and unintentional medication non-adherence: A comprehensive framework for clinical research and practice? A Discussion Paper. Int J Nurs Stud, 2007; 44:1468–1477.
65.
ClossonEF, MittyJA, MaloneJ, et al.Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: A Qualitative Study. AIDS Care, 2017; 30:191–198.
66.
HoornenborgE, KrakowerDS, PrinsM, et al.Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. AIDS, 2017; 31:2179–2191.
67.
CalabreseSK, UnderhillK. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: A call to destigmatize “Truvada Whores.”. Am J Public Health, 2015; 105:1960–1964.
68.
RodriguesIB, ArmstrongJJ, AdachiJD, et al.Facilitators and barriers to exercise adherence in patients with osteopenia and osteoporosis: A systematic review. Osteoporos Int, 2017; 28:735–745.
69.
NewmanCE, BonarM, GrevilleHS, et al.Barriers and incentives to HIV treatment uptake among Aboriginal people in Western Australia. AIDS, 2007; 21(Suppl 1):S13–S17.
70.
GriersonJ, KoelmeyerR, PittsM. Tracking Changes: Tracking the Experiences of Starting and Switching Highly Active Antiretroviral Therapy in Australia. Monograph Series Number 85. Melbourne, Australia: The Australian Research Centre in Sex, Health and Society, La Trobe University, 2011.
71.
GriersonJ, KoelmeyerRL, SmithA, et al.Adherence to antiretroviral therapy: Factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians. HIV Med, 2011; 12:562–569.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
